GB001(前列腺素D2受体2拮抗剂)治疗中重度嗜酸性哮喘的2b期试验结果
这项2b期随机双盲安慰剂对照多中心研究纳入血嗜酸性粒细胞≥250 cells/μL的中重度哮喘患者480例,评估GB001(20/40/60 mg每日一次)对24周内哮喘恶化的影响。GB001各剂量组哮喘恶化比值比与安慰剂相比均无统计学显著性,但数值上倾向GB001;60 mg组肝酶升高和导致停药的不良事件更常见。
要点
- GB001各剂量未显著降低哮喘恶化风险,但数值上倾向GB001。
- 疗效在高/低2型表型间一致,未随血嗜酸性粒细胞或FeNO升高而增强。
- 60 mg组肝酶升高及导致停药的不良事件更常见。
核心结论
- GB001未显著降低哮喘恶化比值比,但观察到倾向GB001的降低。
- 疗效在高/低2型表型间一致,总体安全性可接受,但60 mg与肝损伤风险相关。
研究设计与样本
- 2b期、随机、双盲、安慰剂对照、剂量范围、平行分组、多中心研究。
- 纳入≥18岁且<75岁、血嗜酸性粒细胞≥250 cells/μL的中重度哮喘患者,在标准治疗基础上加用GB001或安慰剂。
- 患者接受每日一次GB001 20 mg、40 mg、60 mg或安慰剂,共480例接受治疗。
- 主要终点为24周内发生哮喘恶化的患者比例,疗效分析基于意向治疗人群,安全性分析基于至少接受一剂研究治疗的患者。
主要发现
- GB001 20 mg、40 mg、60 mg vs 安慰剂的哮喘恶化OR分别为0.674(95% CI,0.398-1.142)、0.677(95% CI,0.399-1.149)、0.651(95% CI,0.385-1.100)。
- 按基线血嗜酸性粒细胞水平和/或呼出气一氧化氮分析,未显示数值越高疗效越好。
- GB001 60 mg组肝转氨酶升高及导致停药的不良事件较安慰剂、20 mg和40 mg组更常见。
关键数值与推荐
- 主要终点哮喘恶化OR:20 mg为0.674(95% CI,0.398-1.142),40 mg为0.677(95% CI,0.399-1.149),60 mg为0.651(95% CI,0.385-1.100)。
- 纳入标准:血嗜酸性粒细胞计数≥250 cells/μL。
- 给药方案:每日一次GB001 20 mg、40 mg或60 mg或安慰剂。
临床怎么用
- GB001在当前剂量下未显著降低哮喘恶化风险,不支持据此常规用于中重度嗜酸性哮喘。
- 若未来使用DP2拮抗剂,需关注60 mg剂量相关的肝损伤风险并监测肝酶。
- 血嗜酸性粒细胞和FeNO可能无法筛选GB001获益人群。
局限性
- 原文未报告样本量计算依据、各剂量组具体例数及P值。
- 原文未报告次要终点、生活质量或肺功能等详细结果。
- 原文未报告长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population and end points persist. RESEARCH QUESTION: What is the effect of the DP2 antagonist GB001 on asthma worsening in patients with moderate to severe eosinophilic asthma? STUDY DESIGN AND METHODS: In this phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multicenter study, GB001 or placebo was added to standard-of-care treatment in patients with moderate to severe asthma with a blood eosinophil count ≥ 250 cells/μL. Patients aged ≥ 18 years to < 75 years received one of four once-daily treatments (GB001 20 mg, 40 mg, or 60 mg or placebo). The primary end point was the proportion of patients who experienced asthma worsening by 24 weeks. Efficacy analyses were performed for the intention-to-treat population and safety analyses for patients who received at least one dose of study treatment. RESULTS: A total of 480 patients were treated. The ORs for asthma worsening for GB001 20 mg, 40 mg, and 60 mg vs placebo were 0.674 (95% CI, 0.398-1.142), 0.677 (95% CI, 0.399-1.149), and 0.651 (95% CI, 0.385-1.100), respectively. Analysis according to baseline blood eosinophil levels and/or fractional exhaled nitric oxide did not show greater treatment effects with higher values. Elevated liver aminotransferase levels and adverse events leading to discontinuation were more frequent for GB001 60 mg than with placebo, GB001 20 mg, and GB001 40 mg. INTERPRETATION: Although GB001 did not significantly reduce the odds of asthma worsening, reductions favoring GB001 were observed. Treatment effects were consistent regardless of high/low type 2 phenotype. The overall safety profile was acceptable, although GB001 60 mg was associated with risk of liver injury. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03683576; URL: www. CLINICALTRIALS: gov.
引用
- Moss MH, Lugogo NL, Castro M, et al. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022. PMID: 35248549. doi:10.1016/j.chest.2022.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。